GE Healthcare acquires Wave Biotech
UK-based GE Healthcare, a unit of General Electric Company, has acquired Wave Biotech, a US supplier of innovative disposable manufacturing technologies for the biopharmaceutical industry.
UK-based GE Healthcare, a unit of General Electric Company, has acquired Wave Biotech, a US supplier of innovative disposable manufacturing technologies for the biopharmaceutical industry.
The acquisition, which includes subsidiary Wave Europe, will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceuticals such as antibodies and vaccines. Financial terms were not disclosed.
Wave Biotech develops and manufactures single-use bioreactors that are designed to replace traditional and more expensive stainless steel tanks and piping. The patented products offer considerable advantages, such as more rapid installation, and significantly lower costs by eliminating the need for cleaning and validating between batches.
'The combination of GE Healthcare and Wave Biotech will allow us to expand into new applications and to create a broad offering of added value tools and services for biopharmaceutical manufacture,' said Ann O'Hara, general manager of GE Healthcare's BioProcess business.
'Our customers will benefit greatly from the global presence and the r&d resources that GE Healthcare brings to the table,' added Dr Vijay Singh, president and founder of Wave Biotech. 'The integration of single-use cell culture with GE Healthcare's existing filtration and downstream operations will provide a host of new disposable solutions to this growing industry.'
